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Identification of pharmacological chaperones as potential
therapeutic agents to treat phenylketonuria
Abstract
Phenylketonuria (PKU) is an inborn error of metabolism caused by mutations in phenylalanine
hydroxylase (PAH). Over 500 disease-causing mutations have been identified in humans, most of which
result in PAH protein misfolding and increased turnover in vivo. The use of pharmacological
chaperones to stabilize or promote correct folding of mutant proteins represents a promising new
direction in the treatment of misfolding diseases. We performed a high-throughput ligand screen of over
1,000 pharmacological agents and identified 4 compounds (I-IV) that enhanced the thermal stability of
PAH and did not show substantial inhibition of PAH activity. In further studies, compounds III
(3-amino-2-benzyl-7-nitro-4-(2-quinolyl)-1,2-dihydroisoquinolin-1-one) and IV
(5,6-dimethyl-3-(4-methyl-2-pyridinyl)-2-thioxo-2,3-dihydrothieno[2,3- d]pyrimidin-4(1H)-one)
stabilized the functional tetrameric conformation of recombinant WT-PAH and PKU mutants. These
compounds also significantly increased activity and steady-state PAH protein levels in cells transiently
transfected with either WT-PAH or PKU mutants. Furthermore, PAH activity in mouse liver increased
after a 12-day oral administration of low doses of compounds III and IV. Thus, we have identified 2
small molecules that may represent promising alternatives in the treatment of PKU.
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Four hit compounds found to stabilize PAH in the 
HTS and further detailed fluorescence analyses. (A) 
Representative thermal denaturation profiles of WT-
PAH in the absence (black) or presence of 100 μM of 
the hit compounds I (red), II (green), III (light blue), 
and IV (dark blue), resulting from the HTS procedure 
as monitored by ANS fluorescence. (B) Chemical 
structures of compounds I, II, III, and IV.
Table 
Half-denaturation temperatures and thermal upshifts for WT-PAH 
in the absence or presence of hit compounds and concentration 
of the compounds for half-maximal binding
Compound	 T0.5A	(°C)	 ΔT0.5	(°C)	 C0.5B	(μM)
No ligand 49.5 ± 1.2 – –
Compound I 52.1 ± 0.9 2.6 0.7 ± 0.1
Compound II 52.2 ± 1.3 2.7 14.0 ± 3.6
Compound III 63.1 ± 2.9 13.6 5.1 ± 1.2
Compound IV 56.7 ± 1.5 7.2 2.6 ± 0.4
AData are mean ± SD from at least 3 independent experiments. Thermal 
upshift (ΔT0.5) is calculated as the difference between the average T0.5 
values determined in the presence and absence of 100 μM compound 
(in 2.5% DMSO) by ANS-monitored thermal unfolding. BC0.5 values 
provide apparent binding affinities and are best-fit parameters obtained 
from experiments shown in Figure 2 as described in Methods.
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Effects of compound III and IV on the stability and folding of WT and 
mutant proteins. The 8-anilino 1-naphthalene sulfonic acid–based 








































denaturation profiles of 
WT-PAH as monitored 
by ANS fluorescence in 
the absence or presence 
of different concentra-
tions of hit compounds 
I (A), II (B), III (C), and 
IV (D). Experiments 
were performed using 
0 (black), 25 (red), 50 
(green), and 100 (light 
blue) μM of each com-
pound in 2.5% DMSO. 
Plots are representative 
of at least 3 independent 
experiments. Insets show 
titrations of WT-PAH 
with compounds I–IV 






























































Enzyme kinetic parameters for WT-PAH and effect of hit compounds I–IV (100 μM)
Compound	 	 	 BH4A	 	 	 l-PheB
	 Preincubation	with	l-Phe	 No	preincubation	with	l-Phe
	 Vmax		 Km		 Vmax		 Km		 Vmax		 S0.5		 Hill	coefficient		
	 (μmol	l-Tyr/min	×	mg)	 (μM)	 (μmol	l-Tyr/min	×	mg)	 (μM)	 (μmol	l-Tyr/min	×	mg)	 (μM)	 (h)
No ligand 3.41 ± 0.24 41 ± 8 0.82 ± 0.03 23 ± 3 3.47 ± 0.07 136 ± 5 2.1 ± 0.2
Compound I 3.52 ± 0.41 55 ± 14 0.80 ± 0.05 26 ± 5 3.02 ± 0.08 118 ± 5 2.6 ± 0.3
Compound II 2.96 ± 0.10 36 ± 3 0.81 ± 0.05 24 ± 4 3.77 ± 0.13 156 ± 10 1.8 ± 0.1
Compound III 2.87 ± 0.14 35 ± 4 0.86 ± 0.03 23 ± 3 3.57 ± 0.11 138 ± 8 1.9 ± 0.2
Compound IV 3.11 ± 0.16 66 ± 8 0.85 ± 0.07 36 ± 8 2.43 ± 0.10 131 ± 11 1.6 ± 0.2
Data are mean ± SEM obtained from nonlinear regression analysis from 2 independent experiments, each performed in duplicate. ADetermined at 1 mM l-Phe 
and variable concentrations of BH4 (0–200 μM). Samples were preincubated 5 minutes at 25°C without or with 1 mM l-Phe before activity measurements. BDe-
termined at 75 μM BH4 and variable concentrations of l-Phe (0–1 mM). Samples were preincubated (5 minutes at 25°C) at different l-Phe concentrations before 
activity measurements. The concentration of l-Phe at half-maximal activity ([S]0.5) and the Hill coefficient were obtained from the fittings to the Hill equation.
Figure 
Effect of the hit compounds on the activity of recombinant 
WT-PAH. Activity was measured with 100 μM l-Phe and 
10 μM BH4 (A) or 1 mM l-Phe and 200 μM BH4 (B), in the 
presence of 100 μM of each compound in 2.5% DMSO (also 
present in control sample [C]). Samples were preincubated 
(black bars) or not preincubated (white bars) with the corre-
sponding l-Phe concentration for 5 minutes at 25°C prior to 
the addition of compounds and of BH4 to start activity mea-
surements. Data are mean ± SD of triplicate experiments.
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Effect of hit compounds III and IV on the stability and 
function of tetrameric PAH proteins. (A) SEC determi-
nation of the fraction of remaining tetramer in WT and 
mutant proteins after heat shock at 50°C for 20 minutes 
in the absence or presence of 100 μM of compound III 
and IV in 2.5% DMSO (also present in control sample). 
Data are expressed as area of the tetrameric fraction 
after heat shock related to the area in correspond-
ing samples incubated for 10 minutes at 25°C. Inset 
shows representative SEC profiles obtained for tetra-
meric WT-PAH incubated at 25°C for 10 minutes (solid 
line) or for 2 independent samples treated at 50°C for 
20 minutes with (dashed line) or without (dotted lines) 
filtering through a 0.22-μm pore filter to remove protein 
aggregates. Only the aggregated forms are eliminated 
by filtration. Elution volumes are approximately 15 ml 
for tetrameric forms and approximately 10 ml for aggre-
gates (the void volume of the column). (B–D) Thermal 
inactivation experiments (B, WT-PAH; C, I65T-PAH; D, 
R68S-PAH) performed by 10-minute incubation at the 
indicated temperatures without (circles) or with 100 μM 
of compound III (triangles) and IV (squares) and subse-
quent measurement of PAH activity at 25°C. Data are 
expressed as fractional activity after incubation at dif-
ferent temperatures related to the corresponding activ-
ity after incubation at 25°C and are given as mean ± SD 
of triplicate experiments.
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Effect of 100 μM of compounds III and IV on the correct  
tetrameric assembly of 5 μM WT-PAH, I65T-PAH, and  
R68S-PAH mutants
Protein	 Compound	 k(102)(min–1)A	 T50	(°C)b
WT None 6.9 ± 0.8 52.1
 III 3.3 ± 0.5 54.0
 IV 2.6 ± 0.4 55.2
I65T None 16.2 ± 3.4 49.6
 III 11.4 ± 1.5 50.6
 IV 9.2 ± 1.0 52.6
R68S None 17.0 ± 4.6 49.5
 III 13.3 ± 3.5 50.4
 IV 11.1 ± 3.4 52.9
AFirst-order rate constants (k) for tetramer decay at 50°C as mea-
sured by SEC. BCalculated from the inactivation experiments shown 
in Figure 4, B–D.
research article






































Effect of stabilizing hit compounds on the activity, protein level, and kinetics of degradation/synthesis of WT-PAH and PKU mutants. (A and B) 
Effect of compounds III (black bars) and IV (white bars) on activity (A) and protein measured by Western blot (B) of WT-PAH and PKU mutants 
transiently expressed (24 hours) in A293 cells. Values are given as mean ± SD of 3–4 independent expression experiments and are compared 
with controls for the corresponding PAH protein, with specific activities (nmol l-Tyr/min × mg): 7.1 ± 2.3 (WT-PAH), 1.7 ± 0.6 (I65T-PAH), 
3.3 ± 0.4 (R68S-PAH), and 4.9 ± 1.9 (R261Q-PAH). The activity of R252W-PAH was <0.01 nmol l-Tyr/min × mg protein (the detection limit) 
under all conditions tested and thus not considered reliable. ANOVA tests, *P < 0.05; **P < 0.01. (C) Western blot analysis of the degradation of 
WT-PAH and I65T-PAH after transient transfection of A293 cells (18 hours) followed by inhibition of protein translation by puromycin (10 μg/ml). 
The half-lives (t1/2) for I65T-PAH (in hours) were 5.0 ± 1.0 (control), 4.8 ± 1.1 (with compound III), and 6.8 ± 0.8 (with compound IV). (D) Kinetics 
of synthesis of WT-PAH in cell-free RTS without and with compounds III and IV. Data (given as mean ± SD of 3–4 independent experiments) 
refer to labeled PAH synthesized after 15.0 (black), 22.5 (light gray), and 30.0 (dark gray) minutes, measured by densitometry and normalized 
with respect to the corresponding control sample after 30-minute synthesis in the absence of compounds (100%). In all experiments, compounds 
are present at 40 μM in 1% DMSO, which is also added in control samples.
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Thermal denaturation monitored by ANS fluorescence and measurement of 

































































Effect of the hit compounds III and IV on PAH activity (A) and immu-
noreactive protein levels determined by Western blot (B) after 12-day 
administration of 5 mg/kg/d to WT C57BL/6 mice. The control group 
was fed with a placebo containing 10% DMSO in water. PAH activi-
ties are given as mean ± SD for each group (n = 5). Immunoreactive 
PAH are represented as ratios between the signal obtained for each 
liver extract from treated animals and the average signal in the control 
group (and expressed as mean ± SD for each group; n = 5). Statisti-
cally significant differences between treated and control groups are 
based on ANOVA tests and expressed as *P < 0.05.
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